Dr. Edward D. Ball, MD

Dr. Ball practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Ball's NPI, 1093740110, was assigned on July 11, 2006. Dr. Ball graduated from Cleveland Medical College, Homeopathic in 1976. Dr. Ball holds California license G84752.

Dr. Ball's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6060.

Dr. Ball's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Ball is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ball practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Ball's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Ball is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Ball's licenses on file in 4 states: California, New Hampshire, Pennsylvania and Ohio.

Dmand AI lists chronic anemia, chronic leukemia, fluid and electrolyte imbalances, immune deficiency disease, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Ball treats.

CMS data shows 298 Medicare services from Dr. Ball across 3 procedure codes in 2024, for 71 Medicare patients. Medicare paid $21,362 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 71 Medicare patients who saw Dr. Ball in 2024. The largest group is 65 to 74, with 44 patients. 69% of them have high cholesterol, and 55% have high blood pressure. 15% are also on Medicaid. Their average risk score is 2.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ball's median patient age at 70, with 43% women.

In 2024, Dr. Ball wrote 582 Medicare Part D claims for 39 patients. 67% of them were for generic drugs. CMS names the drug for 402 of them, across 18 drugs with 11 or more claims each, at $2,562,328 in total drug cost. In 2023, CMS named 377 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Ball for performance year 2024, reported as part of a group.

Dmand AI links 190 papers to Dr. Ball, published from 2005 to 2025. 2017 was the busiest year, with 5. The most frequent topics are Antibodies, Monoclonal, Leukemia, Myeloid, Acute and Hematopoietic Stem Cell Transplantation. Dr. Ball has published most often in Bone Marrow Transplant. Dr. Ball's most frequent co-authors are John Lister, MD, Ewa K. Carrier, MD and Peter R. Holman, MD.

Dmand AI links Dr. Ball to 13 clinical trials, 5 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Graft vs Host Disease and Leukemia, Myeloid. Medical College of Wisconsin sponsors the most, 3.

CMS Open Payments shows 14 general payments to Dr. Ball from 9 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 66% of the total. Pharmacyclics LLC, An AbbVie Company paid the most, $1,923.

Dmand AI lists 4 awards for Dr. Ball, most recently CMS Stage 1 EHR in 2013.

Dr. Ball graduated from Cleveland Medical College, Homeopathic in 1976.

Dr. Ball is in network with 14 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.